The Latest Breaking News from Novo Nordisk

A recent clinical trial of Wegovy showed that 17 percent of patients on the drug left the trial because of side effects.

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks to fewer side effects for patients. Even a partial replacement for chemotherapy could make it a $140 billion market -…

New medications like Wegovy are changing the way people lose weight and manage obesity, but many Medicaid beneficiaries can't get them.

Here's what could happen next to Amgen shares.

The stock market rallied this week, with the Nasdaq regaining its 50-day on a semi-dovish Fed, a tame jobs report and a huge Apple buyback.

Pharma companies are slashing insulin production in favour of more lucrative weight-loss drugs.

Novo Nordisk, which is now Europe’s most valuable company, also reports strong sales of diabetes drug Ozempic

Novo Nordisk stock dipped Thursday after sales of weight-loss drug, Wegovy, nearly doubled, but missed even more bullish expectations.

The drugmaker increased its market share of the diabetic treatment market by 1.8 percentage points and now has a 34-percent share of the market.

Futures rose after the stock market erased big Fed-led gains as AI plays such as Nvidia retreated. Carvana soared on earnings.

As Google stock gaps up and gets volatile, Novo Nordisk sets up while a hot IPO and leading chipmaker break out.